Semaglutide in Children Aged 6-11: Novo STEP Young Phase 3 Results, Safety, and the Timeline to Possible Approval

On September 7, 2026, Novo Nordisk announced first Phase 3 results from STEP Young. The trial tested once-weekly semaglutide — the same medicine sold as Wegovy for adults and teens — in 165 children aged 6 to under 12 years with obesity. Both groups also received a reduced-calorie diet and more physical activity. At week 68, 40.4% of children on semaglutide had a body mass index (BMI) below the obesity threshold. In the placebo group, the same number was 0%. More than 85% of the children enrolled had class II or III severe obesity at the start. Novo said the safety profile matched what was seen in earlier adult and teen trials. The company reported no new safety concerns and no signals for growth or puberty.

Wegovy is approved in the United States for adolescents 12 years and older with obesity. It is not approved below age 12. Novo has not announced a supplemental filing with the FDA to add a younger pediatric indication, and detailed STEP Young results will not be presented in full until ObesityWeek 2026 in Washington DC November 14-17.

Parents of children aged 6-11 with severe obesity are already asking pediatricians about semaglutide. This piece walks through what STEP Young tested, what the topline did not answer, and the treatment landscape for younger children today. It covers the STEP TEENS data behind the current teen approval, long-term follow-up from teen bariatric surgery studies, the likely regulatory timeline, cost and insurance realities, the ethical debate about medicating younger children, and a checklist of questions to bring to your pediatrician.

STEP Young was a Phase 3 randomized double-blind placebo-controlled trial that ran in multiple countries. It enrolled 165 children aged 6 to under 12 years with obesity. Children were randomized to once-weekly semaglutide by injection or to placebo. Both groups also received a reduced-calorie diet and more physical activity throughout the trial. The top semaglutide dose was 1.7 mg or 2.4 mg based on the child's starting weight. That is lower than the 2.4 mg adult dose for the smaller-weight children. Treatment ran for 68 weeks with additional endpoints tracked through week 104.

The enrolled group was heavy at baseline. More than 85% had class II or class III severe obesity. In adult terms, class II means a BMI of 35 or higher. Class III (sometimes called severe or morbid obesity) means a BMI of 40 or higher. In children, the definition uses percentiles. Obesity is a BMI at or above the 95th percentile for age and sex. Severe obesity is 120% or more of the 95th percentile, per the American Academy of Pediatrics (AAP).

The primary result was that 40.4% of the semaglutide group had a BMI below the obesity threshold at week 68. In the placebo group, the same figure was 0%. Both groups had the same lifestyle support throughout. Novo said the safety profile matched earlier pediatric and adolescent trials with semaglutide and liraglutide. There were no new safety concerns, and no signals related to growth or puberty.

Those two safety points matter. Younger children are still growing. Any drug that lowers appetite raises a real question about slowing height gain or affecting puberty timing. Novo's early read that no such signals were seen is preliminary. Full results at ObesityWeek 2026 will show the specific measurements. But the topline reads as reassuring.

STEP Young was designed to prove short-term efficacy and safety in one specific group: children aged 6 to under 12 with obesity, most of them with severe obesity, over 68 weeks. That is a real contribution to what is known about semaglutide in younger children. It is not the whole picture that parents are asking about.

STEP Young did not test what happens when children stop the drug. In adult and adolescent studies, weight regain starts within months of stopping semaglutide. About two-thirds of lost weight returns at one year off treatment. Whether the same pattern holds in children is not answered by the topline. Nor is the question of what happens if a child stops during a growth spurt.

STEP Young did not test the long-term (5-year, 10-year) safety profile in children. Younger children who start semaglutide today would potentially take it for decades. Whether long-duration exposure affects thyroid biology, pancreas function, or future fertility differently than shorter adult exposure is not known. A 68-week trial cannot answer that question.

STEP Young did not compare semaglutide against the strongest lifestyle-only option AAP now recommends. That option is a program of 26 or more contact hours over 3 to 12 months. The comparator was a lifestyle-modification instruction plus a placebo injection. That is not the same as a structured intensive treatment program. This matters because AAP guidelines still put intensive behavioral treatment first. Medication and surgery come later for children who need more.

STEP Young did not test children with milder obesity. The 15% or so of participants in the milder range are a smaller subgroup than the trial was powered to analyze on their own. Whether a child with a BMI just above the 95th percentile without severe obesity would benefit as much is not clear from these results.

The AAP released updated Clinical Practice Guidelines in January 2023. It was the first major update in 15 years. The guideline covers how to evaluate and treat children and teens with overweight and obesity. It recommends early referral for children aged 6 and older. It also allows intensive treatment for children aged 2-5 with overweight or obesity.

The first line of treatment is Intensive Health Behavior and Lifestyle Treatment (IHBLT). This means 26 or more contact hours over 3 to 12 months. The care team should include a physician, dietitian, and behavioral health provider. Access to IHBLT programs varies widely by region and by insurance coverage. Many U.S. counties do not have one within reach.

For drug treatment, the 2023 AAP guideline says clinicians should offer weight-loss medication (as an add-on to lifestyle care) to children aged 12 and older with obesity, per FDA age labels. The current approved options for the 12-and-older group include liraglutide (Saxenda, approved in 2020 for ages 12+), semaglutide (Wegovy, approved December 2022 for ages 12+), phentermine (approved for ages 16+), orlistat (approved for ages 12+), and setmelanotide (Imcivree, approved for ages 6+ for specific rare genetic obesity syndromes such as Bardet-Biedl and hypothalamic obesity).

For children aged 6-11, no GLP-1 receptor agonist is currently FDA-approved. GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after meals. Semaglutide is a synthetic peptide version that lasts longer in the body and mimics that satiety signal. Setmelanotide is the only FDA-approved obesity medication in this age group. It is used only for a small number of children with confirmed rare genetic diagnoses.

Bariatric surgery for teens is recommended by the AAP for children aged 13 and older with severe obesity (BMI ≥120% of the 95th percentile). Surgical evaluation before age 13 is uncommon. It is not recommended outside very specific clinical circumstances.

The closest comparison for STEP Young is STEP TEENS. That Phase 3 trial supported the December 2022 FDA approval of Wegovy for teens 12 to 17 years old. STEP TEENS was published in the New England Journal of Medicine in November 2022 (Kelly and colleagues; NEJM 2022;387:2245-2257).

STEP TEENS enrolled 201 teens aged 12-17 with obesity. That meant a BMI at the 95th percentile or above, or between the 85th and 95th percentile with at least one weight-related health condition. Teens were randomized 2:1 to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Both groups got lifestyle support. The primary result was a 16.1% mean reduction in BMI in the semaglutide arm. Placebo showed a 0.6% increase. The between-group difference was 16.7 percentage points (p<0.001).

Secondary results were strong. 73% of teens on semaglutide lost 5% or more of their body weight. 53% saw a 15% or greater reduction in BMI, versus 5% in placebo. Cardiometabolic risk factors improved: waist circumference, HbA1c, LDL cholesterol, triglycerides, and ALT (a liver enzyme) all shifted toward healthier ranges. Gastrointestinal side effects (nausea, vomiting, diarrhea) were the most common adverse events. They were mostly mild to moderate.

STEP TEENS set the current expectation. Semaglutide works in teens at levels close to adults. The tolerability profile is close too. STEP Young extends that finding to younger children. But the two trials used different primary endpoints. STEP Young measured the share of children below the obesity threshold at week 68. STEP TEENS measured the percent change in BMI. A direct comparison waits for the full ObesityWeek dataset.

For teens whose obesity is severe enough to warrant surgical evaluation, Teen-LABS is the main source of long-term outcomes data in the United States. Teen-LABS enrolled 242 teens aged 19 and younger. They had metabolic and bariatric surgery at five U.S. centers between 2007 and 2012. The study has followed them for more than a decade.

Five years after Roux-en-Y gastric bypass (RYGB), Teen-LABS participants averaged a 26% reduction in total body weight. That is roughly a 13 kg/m² drop in BMI. Sleeve gastrectomy participants averaged 27% total body-weight loss over the first 3 years. In a longer follow-up study (FABS-5+), mean body-weight loss 8 years after RYGB was 29%. Mean BMI dropped 16.9 kg/m².

Surgical resolution of comorbid conditions was strong: 100% resolution of type 2 diabetes, impaired fasting glucose, and high blood pressure at 5 years. 92% resolution of impaired liver enzymes. 83% resolution of high cholesterol/triglycerides. These are numbers no medication currently reaches.

Surgical trade-offs are real. Risks include nutritional deficiencies (iron, B12, folate), the need for lifelong vitamin supplements, occasional re-operations, and a small but nonzero surgical mortality risk. Bariatric surgery is not offered to children below age 13 outside of exceptional cases. So it is not an option for the STEP Young population.

The policy question STEP Young raises is whether earlier medical treatment in children aged 6-11 with severe obesity might reduce the number who eventually need surgery in the teen years or adulthood. STEP Young alone cannot answer that. It requires long-term follow-up of children who receive early treatment versus those who do not.

Novo Nordisk has not announced a supplemental FDA filing to expand Wegovy's label to children under 12. The typical path is to submit a supplemental new drug application (sNDA) with the full STEP Young dataset and a proposed pediatric label. The FDA reviews sNDAs on a 10-month standard timeline or a 6-month priority timeline.

Given the ObesityWeek 2026 timing (November 14-17, 2026), an sNDA filing in the first half of 2027 is a plausible earliest-case scenario. That would put a possible FDA action date in late 2027 or 2028. Novo has not confirmed this timeline. The FDA has previously required post-approval studies for pediatric obesity indications and may do so again.

Before any label expansion, some clinicians may consider off-label use in children aged 6-11 with severe obesity. This is more likely if other options have been tried without success. Off-label prescribing is legal in the United States. But it shifts liability to the prescriber and often is not covered by insurance for uses outside the FDA label. Pediatric endocrinologists and obesity medicine specialists will likely be the first physicians in these decisions. Many will use institutional review or peer consultation for off-label pediatric use of a new drug class.

Compounded semaglutide from telehealth vendors is not an appropriate route for a child. The FDA closed the shortage-based compounding pathway for GLP-1s in Q1 2025. Enforcement has ramped up through 2026. Even during the shortage window, compounded semaglutide was not tested in children. Dosing was often unclear. The American Academy of Pediatrics has warned against compounded GLP-1 use in children.

Wegovy's list price (WAC, or wholesale acquisition cost — the sticker price manufacturers publish before rebates and discounts) is $1,349 per 28-day supply as of mid-2026. Novo Nordisk reports that about 90% of commercially insured Wegovy patients pay $0 to $25 per month through insurance and the Wegovy savings offer. That number is for the adult and adolescent population.

Pediatric coverage is a separate question. Insurance plans that cover Wegovy for teens usually require documentation of the age label and often specific health conditions. If the FDA expands the label to include children aged 6-11 in the future, insurance coverage rules would likely lag by 6-18 months. That is because pharmacy benefit managers (PBMs — the middlemen who run prescription drug benefits for insurers and employers) take time to update formulary rules.

The November 2025 pricing agreement between the Trump administration, Eli Lilly, and Novo Nordisk cuts Medicare and Medicaid prices for GLP-1s. Injectable Wegovy will be $245 per month via Medicare with a $50 copay. TrumpRx launches in January 2026 at $350 per month, trending down to $245. Whether these prices flow through to pediatric prescriptions depends on the specific rules. Medicaid coverage for pediatric obesity varies a lot by state. Medicare does not typically cover pediatric prescriptions, since Medicare eligibility begins at age 65 or with certain disability qualifications.

For uninsured families or families whose insurance does not cover Wegovy, direct-to-consumer options through NovoCare have been $499 per month for cash-pay adult Wegovy as of September 2026. TrumpRx is designed for uninsured and cash-pay adult buyers. Its rules for pediatric prescriptions, if the label expands, are not yet published.

Access to an intensive lifestyle-treatment program (IHBLT) is often the first cost barrier, not medication. Fewer than 1 in 4 U.S. counties has a pediatric obesity treatment program that meets the AAP-recommended 26-contact-hour standard. Where a program exists, insurance coverage for the behavioral treatment component varies widely.

STEP Young lands in the middle of an ongoing debate. Pediatricians, ethicists, parents, and public-health researchers disagree about whether medicating younger children is the right response to the childhood obesity epidemic.

Supporters of medical treatment point to several arguments. Childhood obesity, especially severe obesity, tracks strongly into adult obesity. It multiplies lifetime risk of type 2 diabetes, cardiovascular disease, MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH), sleep apnea, and joint problems. Delaying treatment for children who cannot lose weight through lifestyle care alone can lock in long-term disease burden. The bariatric surgery data show that severe adolescent obesity is treatable with dramatic effect but with real surgical risk. If a medicine can prevent the need for surgery, that is a real benefit.

Critics of expanding medication to younger children raise several concerns. First, long-term safety data in children exposed to GLP-1 drugs for decades does not yet exist. Second, treating obesity as mainly a drug problem may pull attention from the food environment, family-level nutrition support, activity access, and social factors that drive childhood obesity in the first place. Third, weight-focused programs in younger children can raise the risk of disordered eating and body-image problems, especially in girls. Pediatric guidelines have generally been cautious about weight-loss framing in prepubertal children. Fourth, if the medicine works only while taken, a 7-year-old starting treatment faces decades of drug use. That raises questions about cost, adherence, and side effects piling up over time.

The AAP guideline directly acknowledges these tensions. It recommends that treatment decisions be individual, family-centered, and paired with structured behavioral support. Medication in isolation is not the recommended path. STEP Young does not resolve the debate. It gives one more piece of evidence that will shape how it plays out.

If you are the parent of a child aged 6-11 with obesity and you are thinking about what STEP Young might mean for your family, a useful conversation with your pediatrician or a pediatric obesity specialist covers the following:

Where is my child on the growth chart, and by which measure? BMI percentile for age and sex, waist circumference, blood pressure, and metabolic labs (fasting glucose, HbA1c, lipid panel, ALT) give a clearer picture than weight alone. Class I, II, or III severity substantially changes treatment recommendations.

What lifestyle interventions have we tried, and at what intensity? AAP guidelines recommend 26 or more contact hours of intensive behavioral treatment as first-line. If your child has not had access to an IHBLT program or a comparable multidisciplinary treatment, that is often the recommended next step before considering medication.

Are there weight-related comorbidities today? Type 2 diabetes, prediabetes, sleep apnea, elevated liver enzymes, joint pain, or psychosocial distress raise the urgency of treatment and can affect coverage decisions.

What medications are appropriate for my child's age today? As of September 2026, no GLP-1 receptor agonist is approved for children under 12 in the United States outside of setmelanotide for specific rare genetic obesity syndromes. Ask specifically about the FDA-approved options and their evidence base.

How does my pediatrician view off-label use in younger children? Some specialists may consider off-label prescribing of Wegovy or Saxenda for children under 12 with severe obesity and failed lifestyle treatment. Others will not. This is a legitimate area of clinical disagreement, and the right answer depends on your child's specific situation and the specialist's experience.

Should we get on a waiting list for STEP Young follow-up trials or open-label extensions? Novo may run additional pediatric studies, and specialist centers may be invited to enroll. If your child's obesity is severe and other options are limited, participation in a clinical trial gives access to the drug plus close monitoring.

What is the family plan around food, activity, sleep, and screen time? Medication addresses one variable. Whether or not you pursue pharmacotherapy, the AAP guideline emphasizes that treatment happens in a family context. A concrete plan matters more than a prescription pad in most cases.

This piece is educational and reflects publicly available information as of September 8, 2026. It is not medical advice and is not a substitute for a conversation with a qualified pediatrician or pediatric obesity specialist. Peptide profile background: semaglutide on Peptidelist.org.